The 10 most recent market catalysts affecting $AUTL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 85
Autolus Therapeutics Reports Third Quarter 2026 Financial Results
Autolus Therapeutics announced robust Q3 2026 results, with AUCATZYL net product revenue nearly doubling year-over-year. This strong performance is a significant positive catalyst,…
Nov 6, 2026
Corporate Catalyst
Bearish
Impact 55
Alphabet Dissolves Investment Stake in Autolus Therapeutics
Alphabet has fully divested its equity stake in Autolus Therapeutics, along with Spero Therapeutics and GitLab, as part of a broader portfolio adjustment. This matters because the …
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Autolus Therapeutics Announces Publication of ASH Annual Meeting Abstracts
Autolus Therapeutics has disclosed that abstracts for the upcoming ASH Annual Meeting include positive early data from its ALARIC phase 1 trial. The trial, evaluating Fab-based BCM…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 75
HC Wainwright & Co. Assumes Coverage of Autolus Therapeutics with Buy Rating
HC Wainwright & Co. has assumed coverage of Autolus Therapeutics, assigning a 'Buy' rating and a $10.00 price target. This is a significant positive development for Autolus as it s…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 55
Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
Autolus Therapeutics (AUTL) has filed an 8-K to announce that an abstract for its CARLYSLE trial in srSLE has been published, and updated Phase 1 data will be presented at the ACR …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
The better-than-expected Q2 results for Autolus Therapeutics (AUTL) are a significant corporate catalyst, directly impacting its stock price positively. This performance suggests s…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 65
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est
Autolus Therapeutics filed an 8-K to reaffirm its fiscal year 2026 sales guidance, keeping it at $140 million to $150 million. This is a routine disclosure, but it's noteworthy bec…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
The filing indicates that HC Wainwright & Co. analyst Emily Bodnar has reaffirmed her 'Buy' rating and $10 price target for Autolus Therapeutics. This action signals continued anal…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 85
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.
This headline is a strong positive catalyst for Autolus Therapeutics. Better-than-expected sales for a key product, especially a new one like AUCATZYL, demonstrate successful marke…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 80
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M
Autolus Therapeutics announced preliminary Q2 2026 net product revenue for AUCATZYL of $45 million, exceeding prior expectations. This strong performance has prompted the company t…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.